Immunic, Inc. Doses First Healthy Volunteer in its Phase 1 Clinical Program of IMU-935, a Potentially Best-in-Class RORgt Inverse Agonist

Post by: Geert in Immunic Press Release
Immunic, Inc. Doses First Healthy…
read more
18 Sep 2019
0

Immunic, Inc.’s Interim Dosing Analysis of IMU-838 as Part of its Ongoing Phase 2 CALDOSE-1 Study in Patients with Moderate-to-Severe Ulcerative Colitis Establishes Broad, Potentially Safe and Effective Dose Range

Post by: Geert in Immunic Press Release
Immunic, Inc.'s Interim Dosing Analysis…
read more
10 Sep 2019
0

Complete transaction creating Nasdaq-listed company targeting chronic inflammatory and autoimmune diseases

Post by: glenncv@gmail.com in Immunic Press Release
– Developing Oral Therapies with…
read more
12 Apr 2019
0